Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 380

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 380
---
 certified third -partylaboratories from its participants. For example, we plan to lease a facility in a mature market such as Mexico, and utilize the infrastructure of the laboratories within our consortium to process, if and when their respective market develops. This approach allows us to leverage our operating know -how, such as sample processing and sequencing for bioinformatic data creation, while enhancing capital efficiency, reducing risk, and providing accelerated market access; 188 • Off -site bioinformatics support: to address the scarcity and cost of local expertise, our bioinformatics and data science teams provide cloud -basedanalyses that support local testing efforts. This ensures that our partners receive tailored, localized and precise results, further enhancing our value proposition in the region; • Local laboratory partnerships: many of our services are offered through local laboratory operators who have established distribution networks. These relationships are crucial, as they enable us to reach a broader market while integrating our services with complementary services such as auxiliary blood and other tests that we do not offer, recommended by the physicians involved. This integration makes our offering more appealing to our partners and their customers; • Healthcare providers: physicians play a critical role in the adoption and growth of clinical genomic healthcare. We will support market development initiatives for the participants in the consortium, conducting training programs and events with key opinion leaders to close the gap between technology adoption and the market; • Healthcare professional networks: our prevention solutions will be distinguished by the personalized support provided by the consultations with nutrigenetic specialists. In the medium to long term, we plan to enhance these solutions by developing AI -driventools tailored to the consortium’s local needs. These tools, trained on local data sets, are expected to provide additional support to healthcare professionals, ensuring that our services remain effective in each specific market; • Regulatory collaboration: we work closely with regulatory consultants and agencies to stay ahead of emerging requirements. By understanding and anticipating regulatory needs, we ensure that our offerings are fully compliant, thereby facilitating market adoption to minimizing regulatory risks; • Localized solutions: we adapt our products and services to meet the specific cultural and logistical needs of each market, enabling our partners to increase market adoption. We are committed to providing fast turnaround times, competitive pricing, and logistics expertise to further strengthen our position as the partner of choice; and • Co -development opportunities:we plan to provide our partners with the opportunity to invest in the development of future innovations, driven by the collection of respective localized data and the identification of specific regional needs. This collaborative approach not only accelerates innovation but also